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Lack of the Mitochondrial Protein
Acylglycerol Kinase Causes Sengers Syndrome
Johannes A. Mayr,1,9 Tobias B. Haack,2,3,9 Elisabeth Graf,2 Franz A. Zimmermann,1 Thomas Wieland,2
Birgit Haberberger,2,3 Andrea Superti-Furga,4,10 Janbernd Kirschner,4 Beat Steinmann,5
Matthias R. Baumgartner,5 Isabella Moroni,6 Eleonora Lamantea,6 Massimo Zeviani,6
Richard J. Rodenburg,7 Jan Smeitink,7 Tim M. Strom,2,3 Thomas Meitinger,2,3,8 Wolfgang Sperl,1
and Holger Prokisch2,3,*
Exome sequencing of an individual with congenital cataracts, hypertrophic cardiomyopathy, skeletal myopathy, and lactic acidosis, all
typical symptoms of Sengers syndrome, discovered two nonsense mutations in the gene encoding mitochondrial acylglycerol kinase
(AGK). Mutation screening of AGK in further individuals with congenital cataracts and cardiomyopathy identified numerous loss-of-
function mutations in an additional eight families, confirming the causal nature of AGK deficiency in Sengers syndrome. The loss of
AGK led to a decrease of the adenine nucleotide translocator in the inner mitochondrial membrane in muscle, consistent with a role
of AGK in driving the assembly of the translocator as a result of its effects on phospholipid metabolism in mitochondria.Sengers syndrome (MIM 212350) is an autosomal-recessive
disorder characterized by congenital cataracts, hypertro-
phic cardiomyopathy, skeletal myopathy, exercise intoler-
ance, and lactic acidosis but normal mental development.
Since the first report in 1975 by Sengers et al.,1 about 40
individuals have been described as having this unique
mitochondrial disease.2–8 The clinical course varies from
severe forms that cause death in infancy to more benign
forms that allow survival into the fourth decade. Cause
of death is invariably heart failure due to a hypertrophic
form of cardiomyopathy. Histopathological investigations
have shown abnormal structure of mitochondria and
storage of lipid and glycogen in both skeletal and heart
muscle. In 2002, Jordens et al. described a decrease in
both the amount of skeletal muscle and the activity of
adenine nucleotide translocator 1 (ANT1 [SLC25A4]) in
two families with Sengers syndrome.9 Because mutations
in SLC25A4 (MIM 103220) were excluded by linkage anal-
ysis, Jordens et al. proposed that transcriptional, transla-
tional, or posttranslational events might cause the carrier
deficiency. The phenotype of hypertrophic cardiomyop-
athy, exercise intolerance, and lactic acidemia of Slc25a4-
knockout mice shows a broad overlap with the clinical
findings seen in Sengers syndrome.10 However, the molec-
ular basis underpinning the defect has remained elusive.
To identify the disease-causing sequence variation, we
performed exome sequencing in a single German index
case (54027 in Table 1) with Sengers syndrome. Written
informed consent was obtained from all participants or
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Neuherberg 85764, Germany; 3Institute of Human Genetics, Technische Univ
rics and Muscle Disorders, University Medical Center, Freiburg 79106, Germa
dren’s Hospital, Zurich 8032, Switzerland; 6Division of Molecular Neurogenet
e Cura a Carattere Scientifico, Milan 20126, Italy; 7Nijmegen Center for Mitoch
6500 HB, The Netherlands; 8Munich Heart Alliance, Munich 81675, Germany
9These authors contributed equally to this work
10Present address: Department of Pediatrics, University of Lausanne, Centre H
*Correspondence: prokisch@helmholtz-muenchen.de
DOI 10.1016/j.ajhg.2011.12.005. 2012 by The American Society of Human
314 The American Journal of Human Genetics 90, 314–320, Februarywas approved by the ethical committee of the Technical
University of Munich. The boy was born a dizygotic twin
from unrelated parents of Italian origin. The primary
adaptation was uneventful. Bilateral central cataracts
were noticed in a routine physical examination performed
at day 5. On the boy’s 13th day of life, the family noticed
that the child was very fatigued and had muscular
hypotonia. The next day, he arrived at the hospital with
decompensated cardiomyopathy and tachydyspnea.
Echocardiography revealed massive hypertrophy of both
ventricles. Lactate was 7.3 mmol/liter in plasma (normal
is 0.5–2.2 mmol/L). The boy died on the 18th day of life
as a result of cardiac failure. A muscle biopsy was taken
on the 15th day of life and revealed mild myopathic abnor-
malities and deposition of fine lipid droplets in a histol-
ogical investigation. Activity staining of cytochrome c
oxidase and succinate dehydrogenase was normal.
We performed in-solution targeted enrichment of exonic
sequences from index case 54027 by using the 50 Mb
SureSelect Human All Exon kit from Agilent. The library
was subsequently sequenced as 76 paired-end runs on
the GAIIx from Illumina. Read alignment to the human
genome assembly hg19 was done with Burrows-Wheeler
Aligner (BWA, version 0.5.8) and yielded a total of 9.6 Gb
of sequence data corresponding to an average coverage of
1133 (Table S1, available online). Single-nucleotide vari-
ants and small insertions and deletions were detected
with SAMtools (version 0.1.7). Because Sengers syndrome
is known to be a rare condition, we first excluded all vari-
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Table 1. Genetic and Clinical Findings in Sengers Individuals with AGK Mutations
ID Sex
AGK Mutations Identified Biochemical Investigations Clinical Features
cDNA
(NM_018238.3)
Protein
(NP_060708)
OXPHOS
Defect
ATP
Synthesis
Substrate
Oxidation AO Course CM Cataract Other Clinical Features Literature
54027a male c.306C>T
c.841C>T
p.Tyr102*
p.Arg281*
I, IIþIII,
and V
impaired impaired 1 weeks death at
18 days
yes congenital floppy infant, tachydyspnoea,
lactic acidosis plasma, and CSF
this study
60453 male c.3G>C
c.517C>T
p.Met1Ile
p.Gln173*
normal ND ND 3 months alive for
36 years
yes 3 months motor developmental delay,
muscular hypotonia, exercise
intolerance, normal mental
development, and lactic acidosis
Lalive d’Epinay
et al. (‘‘fall 1’’)3
60455 b male c.412C>T
c.1137_1143del
p.Arg138*
p.Gly380Leufs*16
normal ND ND 1 week death at
11 months
yes congenital muscular hypotonia, moderate
motor retardation, and lactic
acidosis depending on exercise
this study
62014 b female NA NA ND ND ND 1 week death at
7 months
ND congenital muscular hypotonia and motor
retardation
this study
60456 c male c.3G>C
c.672C>A
p.Met1Ile
p.Tyr224*
normal ND ND 3 months alive for
35 years
yes 3 months motor developmental delay,
exercise intolerance, normal
mental development, and lactic
acidosis depending on exercise
Lalive d’Epinay
et al. (‘‘fall 3’’)3
62013 c female NA NA normal ND ND 10 weeks death at
19 years
yes 10 weeks motor developmental delay,
exercise intolerance, normal
mental development, esotropia,
and nystagmus
Lalive d’Epinay
et al. (‘‘fall 2’’)3
60182 d male c.1131þ5G>A
c.1131þ5G>A
splicing defect I, IIþIII, IV,
and PDHc
impaired impaired 1 year death at
12 years
yes 18 months muscular hypotonia, muscle
weakness, and exercise intolerance
Morava et al.
(case 1)6
60183 d female c.1131þ5G>A
c.1131þ5G>A
splicing defect I, IIþIII, IV,
and PDHc
impaired impaired birth alive for
10 years
yes 5 months lactic acidosis and exercise
intolerance
Morava et al.
(case 2)6
60186 female c.1131þ5G>A
c.1131þ5G>A
splicing defect normal impaired impaired 3.5 years alive for
41 years
yes congenital lactic acidosis and
cerebrovascular accident
van Ekeren et al.
(case 12)4
62216 female c.672C>A
c.870del
p.Tyr224*
p.Gln291Argfs*8
I, II, III, IV,
and very
high CS
impaired ND birth death at
10 months
yes 4 months lactic acidosis this study
62217 male c.101þ?_222-?del
c.101þ?_222-?del
ND
ND
I, II, III, IV,
and very
high CS
impaired ND 4 months death at
8 months
yes congenital lactic acidosis, seizures, paresis of
upper-left limb, dilation of brain
ventricles, and axial hypotonia
this study
62218 female c.221þ1G>A
c.1213C>T
splicing defect
p.Gln405*
I, II, III, IV,
and very
high CS
ND ND 10 months alive for
12 years
yes congenital lactic acidosis and severe muscle
weakness
Di Rosa et al.,
(case 3);7 this
study
Abbreviations are as follows: OXPHOS, oxidative phosphorylation; AO, age of onset; CM, cardiomyopathy; CSF, cerebrospinal fluid; NA, no material available; ND, not determined; I, complex I; IIþIII, succinate cytochrome c
oxidoreductase; IV, cytochrome c oxidase; V, oligomycin-sensitive ATPase; PDHc, pyruvate dehydrogenase complex; and CS, citrate synthase.
a Investigated by exome sequencing.
b Individuals 60455 and 62014 are siblings.
c Individuals 60456 and 62013 are siblings.
d Individuals 60182 and 60183 are siblings.
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Figure 1. Distribution of the AGK Mutations and Their Consequences on AGK
Structure of AGK (A) and localization of identified mutations. AGK (B) was not detectable with immunoblot analysis (primary AGK
antibody [1:1,000; rabbit polyclonal; GTX107413, Genetex]) in myoblasts form affected individual 54027 and in fibroblasts of
individuals 60453 and 60455.
(C1) Myoblast control.
(C2 and C3) Fibroblast controls.compound heterozygous or homozygous nonsynonymous
variants affecting genes that encode mitochondrial pro-
teins11 (Table S2). This approach identified a single gene
harboring the compound heterozygous nonsense muta-
tions c.306T>G (p.Tyr102*) and c.841C>T (p.Arg281*)
in AGK (RefSeq NM_018238.3), the gene coding for
mitochondrial acylglycerol kinase (AGK). The parents
and the healthy brother carried a single heterozygous
mutation each, as confirmed by Sanger sequencing.
Mutation screening of AGK (MIM 610345) in 13 individ-
uals with congenital cataracts and cardiomyopathy dis-
covered that there were 12 alleles with predicted loss of
function in ten affected individuals, confirming the causal
nature of AGK variants in Sengers syndrome (Figure 1). All
affected individuals displayed the clinical signs of Sengers
syndrome, but they experienced a varying course of the
disease and had different biochemical alterations; five
individuals had a combined respiratory-chain-complex
deficiency in muscle tissue. Clinical phenotypes of most
individuals have been reported previously (Table 1). For
the remaining individuals, the clinical manifestation and
course of the disease are described in the following five
paragraphs.
Individual 62014 was a girl from healthy nonconsangui-
neous Swiss parents. Bilateral cataracts were noticed when
she was born but were interpreted as rubella embryopathy.
The girl always had muscular hypotonia and failed to
thrive. She died at the age of 7months as a result of sudden
infant death syndrome.
Individual 60455, the younger brother of individual
62014, was born at the 40th week of gestation after an316 The American Journal of Human Genetics 90, 314–320, Februaryuneventful pregnancy. He had a length of 47 cm, a body
weight of 2,620 g, a head circumference of 33 cm, and Ap-
gar scores of 9, 10, and 10. His mother first noticed a cata-
ract in his right eye when he was three days old and
another cataract in his left eye when he was two weeks
old. Therefore, a cataract extraction was performed. Elec-
tro- and echocardiography were normal when the boy
was 2 months of age; there was no lactate elevation in
plasma and urine. When he was 4 months old, a failure
to thrive was noticed. When he was 7 months old,
a moderate concentric hypertrophic cardiomyopathy was
first documented and was thereafter rapidly progressive.
Depending on motor activity, lactate was intermittently
elevated. At the age of 8.5 months, the boy presented
withmuscular hypotonia andmoderatemotor retardation.
Electromyography and nerve-conduction velocity were
normal. Magnetic resonance imaging (MRI) investigation
of his muscle tissue showed hypotrophy without fat infil-
tration, and magnetic resonance spectroscopy revealed
a normal 31P-spectrum of phosphate, phosphocreatine,
and ATP. A muscle biopsy revealed fatty infiltrations in
the muscle fibers, and electron microscopy revealed
abnormal mitochondria. Lactate in the blood and urine
was elevated depending onmuscular activity. At 11months
old, the boy died as a result of heart failure. Autopsy was
performed 15 min after his death; both muscle and heart
tissue showed a normal concentration of L-carnitine. Enzy-
matic investigations of muscle tissue showed normal
activity of creatine kinase and complexes I, II, IIþIII, IV,
and V (ATPase). No abnormalities were found in the liver
or kidneys.10, 2012
Table 2. Investigations of the Mitochondrial Energy Metabolism
in Individual 54027
Enzymatic Investigations in
Muscle Tissue
Individual
54027 Controls
Substrate Oxidation Rates [mmol/h/g protein]
[1-14C]pyruvate þ malate þ ADP 34 263–900
[1-14C]pyruvate þ carnitine þ ADP 52 302–856
[1-14C]pyruvate þ malate (ADP) 15 32–102
[1-14C]pyruvate þ malate þ CCCP 119 304–889
[U-14C]malate þ pyruvate þ
malonate þ ADP
50 282–874
[U-14C]malate þ acetylcarnitie þ
malonate þ ADP
30 273–678
[U-14C]malate þ acetylcarnitine þ
arsenite þ ADP
32 156–378
[1,4-14C]succinate þ acetylcarnitine þ ADP 22 167–488
Enzyme Activities [unit/g protein]
Citrate synthase 161 150–338
Complex I 23 28–76
Complex IþIII 92 49–218
Complex II 57 39–102
Complex IIþIII 32 65–180
Complex III 491 304–896
Complex IV (cytochrome c oxidase) 310 181–593
Complex V (oligomycin-sensitive ATPase) 60 86–257Individual 62216, the only daughter of healthy noncon-
sanguineous Italian parents, died at 9 months of age. She
was born at term by normal vaginal delivery, and her birth
weight was 2,750 g. Growth delay was noted during the
third trimester of pregnancy (50–25th percentile) and again
postnatally (<tenth percentile). When she was 4 months
of age, bilateral cataracts were noted. When she was
4.5 months of age, an ultrasound examination of the heart
showed severe concentric left-cardiac hypertrophy. She
then suffered from recurrent bronchitis. After vitrectomy
removed the cataracts, the baby worsened and died from
cardiac arrest. High lactate was only present during infec-
tions or motor activity. Biochemical analysis of bioptic
and autoptic muscle fragments showed marked reduction
of all respiratory-chain complexes and elevated activity
of citrate synthase.
Individual 62217, a boy, was the third child of reportedly
nonconsanguineous Italian parents. His older sister, who
had hypertrophic cardiomyopathy and congenital cata-
racts, died at 4 days old, and his older brother is alive
and well. At birth, bilateral cataracts and moderate hy-
pertrophy of the interventricular septum were noted.
Two surgical interventions for cataracts were performed
at 2 weeks and 2 months of age, when a paresis of the
upper-left limb was noted. A brain MRI showed thinning
of the corpus callosum and moderate dilation of cerebralThe Americaventricles. Axial hypotonia and hypertonia of the upper
limbs were present. When the boy was 4 months of age,
a cardiac ultrasound examination showed severe left-
ventricular hypertrophy (the posterior wall was 12 mm;
the normal value is <4), modest mitral regurgitation, and
preserved ejection fraction. No pulmonary arterial hyper-
tension was detected. At the same age, he had an episode
of generalized hypertonic seizures with no clonic phase.
Anisocoria of the pupils and severe axial hypotonia were
present. High levels of lactate were detected in his blood.
Analysis of respiratory-chain complexes in the homoge-
nate of a muscle biopsy showed reduction of all activities
except for that of citrate synthase, which was elevated,
whereas activities in fibroblasts and in a liver biopsy were
normal. He died at 8 months old as a result of cardiac
failure.
The case of individual 62218 was published by De Rosa
et al. in 2006.7 At that time, the girl was 7 years old and
had clinical features typical of Sengers syndrome; bilateral
cataracts were noticed at 10 months of age, and hypertro-
phic cardiomyopathy was documented by ultrasound
examination at 18 months of age and stabilized from 7
years of age on. She is now 12 years old. Although her
cardiac conditions are relatively stable under therapy
with propranolol and idebenone, her muscle weakness
has progressively worsened, and she has required the aid
of a wheelchair for distances of more than 100 m. Addi-
tional features include reduced body growth (<tenth
percentile) and a mild neurogenic electromyography
pattern, but she has no sign of CNS involvement (there
is no cognitive regression, cerebellar signs, or pyramidal
or extrapyramidal abnormalities). A recent brain MRI was
normal. One younger brother died at 14 months old as
a result of hypertrophic cardiomyopathy with bilateral
cataracts. Amuscle biopsy showed diffuse complex-IV defi-
ciency with numerous ragged-red fibers. Two younger
siblings, a girl and a boy, are alive and well.
All affected individuals carried mutations that are pre-
dicted to result in truncated proteins that are missing
conserved parts of AGK and that therefore represent loss-
of-function alleles (Figure 1 and Figure S1). In two affected
individuals from Switzerland, we identified a heterozygous
mutation (c.3G>C, p.Met1Ile) altering the AGK initiation
codon in combination with two different nonsense muta-
tions. Three individuals from two more families from The
Netherlands harbored homozygous mutations that the
splice-port algorithm predicted to affect the splice donor
site of intron 16 (c.1131þ5G>A).12 A second heterozygous
splice-site mutation (c.221þ1G>A) affecting the donor site
of intron 4 was found in an Italian individual (62218) in
combination with a heterozygous nonsense mutation
(p.Gln405*). An additional Italian individual, 62217,
showed a homozygous deletion of exons 3 and 4. All vari-
ants identified were absent from 1,200 European control
chromosomes.
Immunoblot experiments confirmed the absence of
full-length AGK in muscle tissue from individual 54027n Journal of Human Genetics 90, 314–320, February 10, 2012 317
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Figure 2. Deficiency in ATP Synthesis
and ANT in Sengers Syndrome
The increased ratio of [1-14C]pyruvate þ
malate þ CCCP over [1-14C]pyruvate þ
malate þ ADP oxidation (A) in affected
individual 54027 (filled square) versus
controls (triangles) indicates a deficiency
in ATP synthesis. A decreased amount of
ANT (B) was detected with immunoblot
analysis in skeletal muscle and in differen-
tiated myoblasts (C) of affected individual
54027. Primary antibodies and their
conditions are as follows: ANT antibody
(1:1,000; mouse monoclonal; MSA02,
Mitosciences) and SDHA (1:30,000; mouse
monoclonal; MS204, Mitosciences).(Figure 1). Measurement of respiratory-chain enzymes in
fresh muscle tissue only indicated a slight reduction in the
activity of complexes I, IIþIII, and V (Table 2). However,
the analysis of 14C-labeled mitochondrial substrate in
600 g supernatants from fresh muscle tissue13 had already
demonstrated a clearly abnormal ratio of CCCP- to ADP-
stimulated oxidation rates in the affected individual, indi-
cating a defective ATP synthesis (Table 2 and Figure 2).
Defects in ATP synthesis either affect the F1FO ATP syn-
thase, the mitochondrial phosphate carrier, or the adenine
nucleotide translocator (ANT).13 Immunodecoration14
with an ANT-specific antibody confirmed the absence of
the inner-mitochondrial-membrane ANT in muscle tissue
(Figure 2). However, normal ANT levels in undifferentiated
myoblast cells generated from the same muscle-biopsy
material suggested that a specific posttranslational defect
of proper inner-membrane ANT assembly only occurs in
differentiated muscle fibers. In agreement with this
hypothesis, myoblast cells of affected individual 54027
lost ANT during differentiation (Figure 2 and Figure S2).
AGK is commonly described as a multisubstrate lipid
kinase that catalyzes the phosphorylation of diacylglycerol
(DAG) and monoacylglycerol (with lower affinity).15
The resulting products, phosphatidic acid (PA) or lyso-
phosphatidic acid (LPA), respectively, can either act as
signaling molecules15,16 or take part in the synthesis of
phospholipids. Furthermore, AGK scavenges mitochon-
drial DAG, which has been reported to induce reactive
oxygen species (ROS) signaling via a pathway mediated
by protein kinase D1.17 It has been shown that DAG kinase
1 in S. cerevisiae has an essential function in membrane-318 The American Journal of Human Genetics 90, 314–320, February 10, 2012lipid biosynthesis in the case of
growth resumption after a stationary
phase, especially when the de novo
fatty-acid biosynthesis was inhibited
by cerulenin.18 AGK might play
a similar function in the mitochon-
dria (Figure 3) of proliferating or
differentiating tissues (e.g., muscle
and heart tissue) that predominately
procure their energy from fat and aredevoid of fatty-acid synthesis; in Sengers syndrome, such
tissues are affected the most. Indeed, the most striking
effect of AGK depletion in PC-3 cells by siRNA has been
a reduction of LPA and PA in mitochondria.15 PA and its
downstream product, cardiolipin, are both found in crys-
tals of ANT,19 the most abundant mitochondrial protein,
which is severely decreased in the muscle tissue of individ-
uals with Sengers syndrome. A disturbed membrane-lipid
composition might also be responsible for the zonular
nuclear cataract, a region of differentiating cells where
the cellular architecture and exact arrangement of the cells
are critical for light transmission and lens transparency.
The clinical manifestation of Sengers syndrome resem-
bles defects of mitochondrial ATP synthesis, either of F1FO
ATP synthase (e.g., TMEM70 [MIM 612418]20 and ATP5E
[MIM606153]21) or of themitochondrial phosphate carrier,
SLC25A3 (MIM600370)13. Symptoms of Sengers syndrome
also resemble the known cardiolipin-metabolism defect
(such as in X-linked Barth syndrome [MIM 302060],22
which is caused by TAZ [MIM 300394]23 mutations) in
terms of neonatal onset of the disease, cardiomyopathy,
andmyopathy. Lactic acidosis is found inSengers syndrome
and in the other defects of ATP synthesis but usually not
in Barth syndrome. Elevated excretion of 3-methylgluta-
conic acid (3-MGA) in urine is found in F1FO-ATP-synthase
deficiency20,21 and in Barth syndrome.24 However, it is
usually not found in Sengers syndrome with ANT defi-
ciency or in the SLC25A3 defect,13 although a mild eleva-
tion of 3-MGA in urine was reported in individual 62218.7
Therefore, Sengers syndrome includes aspects of both
ATP-synthesis and cardiolipin-metabolism defects.
Figure 3. Potential Role of AGK in the Mitochondrial Lipid Metabolism
Abbreviations are as follows: AGK, acylglycerol kinase; CDS, CDP-diacylglycerol synthase; PGS, phosphatidylglycerophosphate
synthase; PTPMT, phosphatidylglycerol-phosphate phosphatase; CRLS, cardiolipin synthase; ANT, adenine nucleotide translocator;
DAK, diacylglycerol kinase; GPAT, glycerol-3-phosphate acyltransferase; LPAAT, 1-acylglycerol-3-phosphate O-acyltransferase; G3P,
glycerol 3-phosphate; LPA, lyso-phosphatidic acid; PA, phosphatidic acid; DAG, diacylglycerol; TAG, triacylglycerol; PL, phospholipid;
CDP-DAG, cytidine diphosphate diacylglycerol; PGP, phosphatidylglycerol-phosphate; PG, phosphatidylglyceroll; CL, cardiolipin; ER,
endoplasmic reticulum; OMM, outer mitochondrial membrane; and IMM, inner mitochondrial membrane.At the moment, it is purely speculative whether the
tissue expression of the four different ANT isoforms corre-
lates with the pathomechanism in Sengers syndrome.
ANT1 encoded by SLC25A4 is the major isoform in muscle
and heart tissue, whereas ANT3 (SLC25A6 [MIM 300151])
is ubiquitously expressed.25 ANT2 (SLC25A5 [MIM
300150]) is mainly associated with smooth muscle
cells,25 and ANT4 (SLC25A31 [MIM 610796]) is mainly ex-
pressed in the liver, testes, and brain.26
In summary, the biochemical data are consistent with
a defined role of AGK in driving the assembly of ANT
and, in some circumstances, respiratory-chain complexes
as a result of its effects on phospholipid metabolism in
mitochondria. Given the strong pre-existing evidence of
mitochondrial dysfunction in Sengers syndrome, exome
sequencing of a single affected individual coupled with
the appropriate filtering of candidates for mitochondrial
functions allowed us to identify AGK variants as the
cause of Sengers syndrome in a significant proportion of
individuals and to reveal an unexpected link between
lipid metabolism and ATP synthesis.Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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